{
    "clinical_study": {
        "@rank": "80606", 
        "arm_group": {
            "arm_group_label": "Palbociclib given to healthy volunteers", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study is intended to quantify the effect of food on the extent of absorption of\n      palbociclib.\n\n      The caloric content of the food and the time of the meals with respect to palbociclib\n      administration  may influence the capacity of the body to absorb the drug.\n\n      High and low calorie meals will be given to the subjects 30 minutes before palbociclib\n      administration as 2 of the 3 conditions to compare with completely absence of food in the\n      body when dosing (fasted).The third condition to test and compare with fasted stage will be\n      the administration of food before and after palbociclib administration.\n\n      This information will help the program to decide wether or not the presence of food when\n      dosing palbociclib help with its absorption and to what extent it does help. Based on the\n      collected information, a recommendation about the administration of palbociclib with food\n      will be provided to patients."
        }, 
        "brief_title": "Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects and/or female subjects of non-childbearing potential between\n             the ages of 18 and 55 years\n\n          -  Evidence of a personally signed and dated informed consent document indicating that\n             the subject (or a legal representative) has been informed of all pertinent aspects of\n             the study\n\n          -  Subjects who are willing and able to comply with all scheduled visits, treatment\n             plan, laboratory tests, and other study procedures\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hematological, renal, endocrine,\n             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or\n             allergic disease\n\n          -  Any condition possibly affecting drug absorption\n\n          -  Male subjects who are unwilling or unable to use a highly effective method of\n             contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01904747", 
            "org_study_id": "A5481021"
        }, 
        "intervention": [
            {
                "arm_group_label": "Palbociclib given to healthy volunteers", 
                "description": "palbociclib given under  fasting 10 hrs overnight; capsule form, 125 mg single dose", 
                "intervention_name": "Palbociclib administered Fasted", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Palbociclib given to healthy volunteers", 
                "description": "palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose", 
                "intervention_name": "Palbociclib administered Fed high calorie", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Palbociclib given to healthy volunteers", 
                "description": "palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose", 
                "intervention_name": "Palbociclib administered Fed low calorie", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Palbociclib given to healthy volunteers", 
                "description": "palbociclib given between moderate calorie meal; capsule form, 125 mg single dose", 
                "intervention_name": "Palbociclib administered Fed moderate calorie", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Food", 
            "Bioavailability", 
            "Fasted", 
            "Fed"
        ], 
        "lastchanged_date": "December 16, 2013", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5481021&StudyName=Characterization%20Of%20The%20Effect%20Of%20Food%20On%20Palbociclib%20%28PD-0332991%29%20Absorption%0A"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06511"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label 4 Sequence 4 Period Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Estimate The Effect Of Food On The Bioavailability Of Palbociclib", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8). It is obtained from AUC (0 - t) plus AUC (t - 8).", 
                "measure": "Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]", 
                "safety_issue": "No", 
                "time_frame": "144 hrs"
            }, 
            {
                "measure": "Maximum Observed Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "144 hrs"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01904747"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)", 
                "safety_issue": "No", 
                "time_frame": "144 hrs"
            }, 
            {
                "description": "AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)", 
                "measure": "Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]", 
                "safety_issue": "No", 
                "time_frame": "144 hrs"
            }, 
            {
                "description": "AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.", 
                "measure": "Area under the Concentration-Time Curve (AUC) from 0 to 72 hrs", 
                "safety_issue": "No", 
                "time_frame": "144 hrs"
            }, 
            {
                "description": "Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.  Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling.  Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.", 
                "measure": "Apparent Oral Clearance (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "144 hrs"
            }, 
            {
                "measure": "Time to Reach Maximum Observed Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "144 hrs"
            }, 
            {
                "description": "Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.", 
                "measure": "Apparent Volume of Distribution (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "144 hrs"
            }, 
            {
                "description": "Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.", 
                "measure": "Plasma Decay Half-Life (t1/2)", 
                "safety_issue": "No", 
                "time_frame": "144 hrs"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Bio-availability Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}